0
Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam...
News & Events
0
Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
Navarra, Spain – August 28, 2025 — Palobiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Dual Antagonist Compounds Targeting...
0
Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain
Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain Pamplona-Iruña, February 27, 2025 – The Navarra biotechnology companies, Palobiofarma and...
0
PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.
Palobiofarma S.L. Announces Positive Top-Line Results from the Phase 2 Trial of Oral PBF-680 in Moderate-to-Severe COPD patients. Primary endpoint was achieved, with PBF-680 demonstrating a...
0
Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients.
Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe...
0
PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
Pamplona, Spain – Palobiofarma S.L. is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of...
0
Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team
Pamplona-Iruña, February 2, 2024.- Palobiofarma has closed a seven-million-euro investment round led by Inveready, through the Inveready Biotech IV fund, the public company Sodena and the...
0
Palobiofarma S.L. Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome
Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s...
0
Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome
[Pamplona, Spain], [May 9th, 2023] – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a...
0
May 4, 2023 Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome.
[May 4, 2023] – [Pamplona, Navarra] – The Foundation for Prader Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L.,...